Benzodiazepine Receptor Binding in Huntington's Disease: [11C]flumazenil Uptake Measured Using Positron Emission Tomography

Overview

Journal Ann Neurol

Specialty Neurology

Date 2000 May 11

PMID 10805336

Citations 14

Authors

G Kunig

K L Leenders

R Sanchez-Pernaute

A Antonini

P Vontobel

A Verhagen

I Gunther

Affiliations

Soon will be listed here.

Abstract

We used positron emission tomography and [11C]flumazenil to analyze the benzodiazepine receptor binding in symptomatic and asymptomatic carriers of the Huntington's disease gene. We found an inverse relationship between [11C]flumazenil and [11C]raclopride binding in the putamen of symptomatic patients, and interpret this result as GABA receptor upregulation.

Citing Articles

Genome-wide screening in pluripotent cells identifies Mtf1 as a suppressor of mutant huntingtin toxicity.

Ferlazzo G, Gambetta A, Amato S, Cannizzaro N, Angiolillo S, Arboit M Nat Commun. 2023; 14(1):3962.

PMID: 37407555 PMC: 10322923. DOI: 10.1038/s41467-023-39552-9.

Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases.

Wilson H, Politis M, Rabiner E, Middleton L Cells. 2020; 9(12).

PMID: 33276490 PMC: 7761606. DOI: 10.3390/cells9122581.

Huntington's Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers.

Cybulska K, Perk L, Booij J, Laverman P, Rijpkema M Molecules. 2020; 25(3).

PMID: 31979301 PMC: 7038198. DOI: 10.3390/molecules25030482.

Insights into GABAergic system alteration in Huntington's disease.

Hsu Y, Chang Y, Chern Y Open Biol. 2018; 8(12).

PMID: 30518638 PMC: 6303784. DOI: 10.1098/rsob.180165.

Alteration of GABAergic neurotransmission in Huntington's disease.

Garret M, Du Z, Chazalon M, Cho Y, Baufreton J CNS Neurosci Ther. 2018; 24(4):292-300.

PMID: 29464851 PMC: 6490108. DOI: 10.1111/cns.12826.